627 related articles for article (PubMed ID: 25421015)
1. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
PLoS One; 2014; 9(8):e105638. PubMed ID: 25166023
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Stein P; Berg JK; Morrow L; Polidori D; Artis E; Rusch S; Vaccaro N; Devineni D
Metabolism; 2014 Oct; 63(10):1296-303. PubMed ID: 25110280
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
Polidori D; Sha S; Mudaliar S; Ciaraldi TP; Ghosh A; Vaccaro N; Farrell K; Rothenberg P; Henry RR
Diabetes Care; 2013 Aug; 36(8):2154-61. PubMed ID: 23412078
[TBL] [Abstract][Full Text] [Related]
6. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
Chen X; Hu P; Vaccaro N; Polidori D; Curtin CR; Stieltjes H; Sha S; Weiner S; Devineni D
Clin Ther; 2015 Jul; 37(7):1483-1492.e1. PubMed ID: 26048186
[TBL] [Abstract][Full Text] [Related]
10. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
Polidori D; Sha S; Ghosh A; Plum-Mörschel L; Heise T; Rothenberg P
J Clin Endocrinol Metab; 2013 May; 98(5):E867-71. PubMed ID: 23585665
[TBL] [Abstract][Full Text] [Related]
11. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Devineni D; Polidori D; Curtin CR; Murphy J; Wang SS; Stieltjes H; Wajs E
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):438-46. PubMed ID: 25907176
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F
Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924
[TBL] [Abstract][Full Text] [Related]
15. Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes.
Mondick J; Riggs M; Sasaki T; Sarashina A; Broedl UC; Retlich S
Diabetes Obes Metab; 2016 Mar; 18(3):241-8. PubMed ID: 26511213
[TBL] [Abstract][Full Text] [Related]
16. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Stieltjes H; Wajs E
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):129-38. PubMed ID: 25500487
[TBL] [Abstract][Full Text] [Related]
17. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
[TBL] [Abstract][Full Text] [Related]
18. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
Tirucherai GS; LaCreta F; Ismat FA; Tang W; Boulton DW
Diabetes Obes Metab; 2016 Jul; 18(7):678-84. PubMed ID: 27291448
[TBL] [Abstract][Full Text] [Related]
20. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
